U.S. markets open in 1 hour 12 minutes
  • S&P Futures

    4,165.75
    +8.00 (+0.19%)
     
  • Dow Futures

    34,316.00
    +60.00 (+0.18%)
     
  • Nasdaq Futures

    13,380.75
    +77.25 (+0.58%)
     
  • Russell 2000 Futures

    2,231.90
    +6.40 (+0.29%)
     
  • Crude Oil

    66.64
    +0.37 (+0.56%)
     
  • Gold

    1,872.40
    +4.80 (+0.26%)
     
  • Silver

    28.69
    +0.42 (+1.49%)
     
  • EUR/USD

    1.2226
    +0.0070 (+0.57%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.69
    +0.88 (+4.68%)
     
  • GBP/USD

    1.4204
    +0.0066 (+0.47%)
     
  • USD/JPY

    108.8990
    -0.3010 (-0.28%)
     
  • BTC-USD

    45,024.78
    -460.54 (-1.01%)
     
  • CMC Crypto 200

    1,259.19
    +61.27 (+5.11%)
     
  • FTSE 100

    7,055.24
    +22.39 (+0.32%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

LAWSUITS FILED AGAINST FGEN, DDD and CAN - Jakubowitz Law Pursues Shareholders Claims

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / April 19, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

FibroGen, Inc. (NASDAQ:FGEN)

CONTACT JAKUBOWITZ ABOUT FGEN:
https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=14844&from=1

Class Period : November 8, 2019 - April 6, 2021

Lead Plaintiff Deadline : June 11, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

3D Systems Corporation (NYSE:DDD)

CONTACT JAKUBOWITZ ABOUT DDD:
https://claimyourloss.com/securities/3d-systems-corp-loss-submission-form/?id=14844&from=1

Class Period : May 6, 2020 - March 1, 2021

Lead Plaintiff Deadline : June 8, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) 3D Systems lacked proper internal controls over financial reporting; and (2) as a result, 3D Systems' public statements were materially false and/or misleading at all relevant times.

Canaan Inc. (NASDAQ:CAN)

CONTACT JAKUBOWITZ ABOUT CAN:
https://claimyourloss.com/securities/canaan-inc-loss-submission-form-2/?id=14844&from=1

Class Period : February 10, 2021 - April 9, 2021

Lead Plaintiff Deadline : June 14, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: they concealed that due to ongoing supply chain disruptions and the introduction of the Company's next-generation A12 series bitcoin mining machines - which had cannibalized sales of the older product offerings - Canaan's 4Q20 sales had declined more than 93% year-over-year compared to its fourth quarter fiscal year 2019 (“4Q19”) sales and more than 93% quarter-over-quarter compared to its third quarter FY20 (“3Q20”) sales.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/641116/LAWSUITS-FILED-AGAINST-FGEN-DDD-and-CAN--Jakubowitz-Law-Pursues-Shareholders-Claims